Drug-tunable multidimensional synthetic gene control using inducible degron-tagged dCas9 effectors

Dirk A Kleinjan, Caroline Wardrope, Si Nga Sou, Susan J Rosser

Research output: Contribution to journalArticlepeer-review


The nuclease-deactivated variant of CRISPR-Cas9 proteins (dCas9) fused to heterologous transactivation domains can act as a potent guide RNA sequence-directed inducer or repressor of gene expression in mammalian cells. In such a system the long-term presence of a stable dCas9 effector can be a draw-back precluding the ability to switch rapidly between repressed and activated target gene expression states, imposing a static environment on the synthetic regulatory circuits in the cell. To address this issue we have generated a toolkit of conditionally degradable or stabilisable orthologous dCas9 or Cpf1 effector proteins, thus opening options for multidimensional control of functional activities through combinations of orthogonal, drug-tunable artificial transcription factors.

Original languageEnglish
Article number1191
JournalNature Communications
Issue number1
Publication statusPublished - 30 Oct 2017


  • Journal Article


Dive into the research topics of 'Drug-tunable multidimensional synthetic gene control using inducible degron-tagged dCas9 effectors'. Together they form a unique fingerprint.

Cite this